Perfect HLA matching and no glucocorticoids-still an imperfect world

Transplantation

Volumn 87, Issue 3, 2009, Pages 319-321

  Braun, William E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; GLUCOCORTICOID; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; DNA; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; FETUS DEATH; HAPLOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; RISK FACTOR; SIDE EFFECT; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; ARTICLE; CHILD PARENT RELATION; FEMALE; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MALE; METHODOLOGY; MONOZYGOTIC TWINS; SIBLING;

DNA; FEMALE; GLUCOCORTICOIDS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PARENT-CHILD RELATIONS; PHENOTYPE; SIBLINGS; TWINS, MONOZYGOTIC;

EID: 61849155806     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318194521b     Document Type: Note

References (27)

1. Walker J, Alloway R, Roy-Chaudhury P, et al. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation. Transplantation 2009; 87: 408.
2. Braun WE, Straffon RA. Long-term results in 35 HLA-identical sibling and 3 HLA-identical parent-child renal allograft recipients. Nephron 1978; 22: 232.
3. Montoliu J, Cheigh JS, Mouradian JA, et al. Delayed hyperacute rejection in recipients of kidney transplants from HLA identical sibling donors. Am J Med 1979; 67: 590.
4. Pfeffer PF, Thorsby E. HLA-restricted cytotoxicity against male-specific (H-Y) antigen after acute rejection of an HLA-identical sibling kidney: Clonal distribution of the cytotoxic cells. Transplantation 1982; 33: 52.
5. Glassock RJ, Feldman D, Reynolds ES, et al. Human renal isografts: A clinical and pathologic analysis. Medicine (Baltimore) 1968; 47: 411.
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
7. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059.
8. Danovitch GM. Handbook on transplantation, 4th Edition. Philadelphia, Lippincott Williams & Wilkins 2005, p 95.
9. Peddi VR, First MR. Diagnosis and treatment of renal dysfunction episodes. In: Norman DJ, Turka LA, eds. Primer on transplantation [ed. 2]. Mt. Laurel, NJ, American Society of Transplantation 2001, Ch 57.
10. McCauley J.The nephrotoxicity of FK506 as compared with cyclospor-ine. Curr Opin Nephrol Hypertens 1993; 2: 662.
11. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
12. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137: 364.
13. Pelletier RP, Akin B, Ferguson RM. Prospective, randomized trial of steroid withdrawal in kidney recipients treated with mycophenolate mofetil and cyclosporine. Clin Transplant 2006; 20: 10.
14. Heemann UW, Azuma H, Tullius SG, et al. The contribution of reduced functioning mass to chronic kidney allograft dysfunction in rats. Transplantation 1994; 58: 1317.
15. Tullius SG, Heemann U, Hancock WW, et al. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg 1994; 220: 425.
16. Glassock R. Concluding remarks. Contrib Nephrol 2007; 157: 169.
17. Tolkoff-Rubin NE, Cosimi AB, Fuller T, et al. IGA nephropathy in HLA-identical siblings. Transplantation 1978; 26: 430.
18. Berger J, Yaneva H, Nabarra B, et al. Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 1975; 7: 232.
19. McDonald SP, Russ GR. Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 2006; 82: 759.
20. Ponticelli C, Traversi L, Feliciani A, et al. Kidney transplantation in patients with IgA mesangial glomerulonephritis. Kidney Int 2001; 60: 1948.
21. Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347: 103.
22. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA ne-phropathy: Resultsofa3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842.
23. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68: 802.
24. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225.
25. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157.
26. Berthoux F, El Deeb S, Mariat C, et al. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 2008; 85: 1505.
27. Suzuki H, Suzuki Y, Aizawa M, et al. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int 2007; 72:319.